<DOC>
	<DOCNO>NCT01797315</DOCNO>
	<brief_summary>Transplant recipient high risk develop skin malignancy . This effect depend one hand immunosuppressive drug relate hand dosage . Based encouraging result previous , retrospective study patient treat Sirolimus ( SRL ) , patient switch immunosuppressive regime include SRL , decrease dosage calcineurin-inhibitors convert former immunosuppression . A conversion SRL-based therapy effective immunosuppression safe regard graft patient survival . This study design ass whether switch SRL-immunosuppressive therapy decrease incidence/reoccurrence skin neoplasm .</brief_summary>
	<brief_title>Prevention Skin Cancer High Risk Patients After Conversion Sirolimus-based Immunosuppressive Protocol</brief_title>
	<detailed_description />
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Recipients renal allograft current actinic keratosis I II successfully treat actinic keratosis III ( inclusion possible immediately complete wound heal surgical excision ) , invasive squamous cell carcinoma ( SCC ) , basal cell carcinoma age 18 year old minimum period 6 month renal transplantation stable renal function calculate creatinine clearance least 40 ml/min write informed consent proteinuria â‰¤ 800 mg/d time enrolment successfully treat solid tumor ( recurrence metastasis last 2 year ) Current Sirolimus Everolimus intake Instable graft function ( creatinine clearance &lt; 40 ml/min ) Graft rejection within 3 previous month Proteinuria &gt; 800 mg/d Noncontrolled hyperlipidemia ( Cholesterol &gt; 7,8 mmol/l ( 300 mg/dl ) , Triglycerides &gt; 4 mmol/l ( 350 mg/dl ) Leucopenia &lt; 2500/nl Thrombocytopenia &lt; 90/nl Pregnancy breastfeed Women childbearing age without highly effective contraception Known allergy macrolides Current participation study Refusal sign inform consent form Neoplasm define inclusion criterion All contraindication SRL ( see package insert , appendix ) Persons detain officially legally official institute Acute infection ( mycotic , viral bacterial ) Current intake substance know nephrotoxicity Severe liver dysfunction Current intake CY3A4inhibitors ( e.g . ketoconazole , voriconazole , itraconazole , telithromycin clarithromycin ) CY3A4inductors ( rifampicin , rifabutin ) sucroseisomaltase deficiency , fructose intolerance , glucosegalactose intolerance azathioprine : know allergy azathioprine 6mercaptopurine , severe bone marrow dysfunction , pancreatitis , vaccination live vaccine tacrolimus : know allergy tacrolimus mycophenolatmofetil : know allergy mycophenolatmofetil , neutropenia , severe active gastrointestinal tract disease , LeschNyhan syndrome KelleySeegmiller syndrome , current intake azathioprine cyclosporine : know allergy cyclosporine , increase intracranial pressure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>